Bosentan Use in Patients With Diabetic Nephropathy
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
There is little doubt of the necessity for further improvement in the prevention and therapy
of end-stage renal disease. Despite the success of ARB in treating diabetic nephropathy, not
all patients obtain satisfactory control of blood pressure, albuminuria and decline in renal
function. Experimental data have provided us with a rationale for the potential added
benefits of ET receptor blockade to the AII inhibition in diabetic renal protection.
Considering the nephroprotective effect of bosentan in diabetic rats, clinical studies are
warranted to assess whether ET receptor antagonism has additive renoprotective effects on top
of AII inhibition.